Time and motion study of a subcutaneous fixed-dose combination of pertuzumab and trastuzumab for the treatment of patients with HER2-positive early breast cancer (PHaTiMa)

被引：0
|
作者：
Gregori, Joaquin Gavila
Miranda, Elena Lopez
Escriva-de-Romani, Santiago
Rodriguez, Begona Jimenez
Novoa, Silvia Antolin
Morales, Luis Fernandez
Calvo, Elena Galve
Cortijo, Lucia Gonzalez
Martorell, Antonia Perello
Ruiz, Julian Lagunar
Santiago, Santiago Gonzalez
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-OT1-12-09
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT1-12-09
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Pertuzumab plus trastuzumab increases survival in patients with HER2-positive breast cancer
    Mayor, Susan
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2014, 75 (11) : 611 - 611
  • [42] Impact of subcutaneous versus intravenous administration of pertuzumab and trastuzumab (PH) for the treatment of HER2-positive breast cancer in Montenegro
    Saric, N. Cicmil
    Lekic, S.
    Lakicevic, J.
    Todorovic, V.
    EUROPEAN JOURNAL OF CANCER, 2022, 175 : S72 - S72
  • [43] Manual injection of subcutaneous trastuzumab vs intravenous infusion for HER2-positive early breast cancer: a time-and-motion study
    De Cock, E.
    Knoop, A.
    Jakobsen, E. H.
    Ribecco, A. S.
    Hauser, N.
    Kritikou, P.
    Millar, D.
    Pivot, X.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S432 - S433
  • [44] Subcutaneous Trastuzumab Combined with Pertuzumab and Docetaxel as First-line Treatment of Advanced HER2-positive Breast Cancer
    Stefanou, Dimitra
    Kokkali, Stefania
    Tripodaki, Elli-Sophia
    Drizou, Maria
    Magou, Elpida
    Zylis, Dimosthenis
    Prevezanou, Maria
    Kapiris, Matthaios
    Nasi, Despoina
    Ntokou, Anna
    Dede, Mary
    Ardavanis, Alexandros
    ANTICANCER RESEARCH, 2018, 38 (11) : 6565 - 6569
  • [45] Patient (pt) preference for the pertuzumab-trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) in HER2-positive early breast cancer (EBC): Primary analysis of the open-label, randomised crossover PHranceSCa study
    O'Shaughnessy, J.
    Sousa, S.
    Cruz, J.
    Fallowfield, L.
    Auvinen, P.
    Pulido, C.
    Cvetanovic, A.
    Wilks, S.
    Ribeiro, L.
    Burotto, M.
    Klingbiel, D.
    Messeri, D.
    Alexandrou, A.
    Trask, P.
    Fredriksson, J.
    Machackova, Z.
    Stamatovic, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S306 - S307
  • [46] Subcutaneous Trastuzumab: A Review in HER2-Positive Breast Cancer
    Heo, Young-A
    Syed, Yahiya Y.
    TARGETED ONCOLOGY, 2019, 14 (06) : 749 - 758
  • [47] Subcutaneous Trastuzumab: A Review in HER2-Positive Breast Cancer
    Young-A Heo
    Yahiya Y. Syed
    Targeted Oncology, 2019, 14 : 749 - 758
  • [48] Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience
    Hall, Benjamin James
    Bhojwani, Ajay Ashok
    Wong, Helen
    Law, Andrea
    Flint, Helen
    Ahmed, Eliyaz
    Innes, Helen
    Cliff, Joanne
    Malik, Zaf
    O'Hagan, Julie Elizabeth
    Hall, Allison
    Sripadam, Rajaram
    Tolan, Shaun
    Ali, Zulfiqar
    Hart, Clare
    Errington, Douglas
    Alam, Farida
    Giuliani, Rosa
    Mehta, Shaveta
    Khanduri, Sheena
    Thorp, Nicky
    Jackson, Richard
    Cicconi, Silvia
    Palmieri, Carlo
    BREAST JOURNAL, 2022, 2022
  • [49] White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an Example
    Christian Jackisch
    Federico Manevy
    Suzanne Frank
    Nicki Roberts
    Jason Shafrin
    Advances in Therapy, 2022, 39 : 833 - 844
  • [50] Patient (pt) preference and satisfaction with the subcutaneous fixed-dose combination of pertuzumab (P) and trastuzumab (H) in pts with HER2-positive early breast cancer (HER2+eBC): Interim analysis of the open-label, randomised cross-over PHranceSCa study
    O'Shaughnessy, J.
    Sousa, S. P.
    Cruz, J.
    Fallowfield, L. J.
    Auvinen, P.
    Pulido, C.
    Cvetanovic, A.
    Wilks, S.
    Ribeiro, L.
    Burotto, M.
    Klingbiel, D.
    Messeri, D.
    Alexandrou, A.
    Trask, P.
    Fredriksson, J.
    Stamatovic, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S42 - S42
12345